

68. Vella V, Nicolosi ML, Giuliano S, Bellomo M, Belfiore A, Malaguarnera R. PPAR- γ agonists as antineoplastic agents in cancers with dysregulated IGF axis. *Front Endocrinol* 2017;8(31):1-15. doi: 10.3389/fendo.2017.00031
69. Shila S, Hemanth G, Tholcopiyan L, Yaongamphi V, Sudha P, Umashankar V, et al. In silico screening of potent ppargamma agonists among natural anticancer compounds of indian origin. *Asian J Pharm Clin Res* 2016;9(4). doi: 10.22159/ajpcr.2016.v9s3.12613
70. Bonofiglio D, Aquila S, Catalano S, Gabriele S, Belmonte M, Middea E, et al. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappab sequence in human MCF7 breast cancer cells. *Mol Endocrinol* 2006;20(12):3083-92. doi: 10.1210/me.2006-0192
71. Lecarpentier Y, Claes V, Vallee A, Hebert JL. Interactions between PPAR gamma and the canonical wnt/beta-catenin pathway in type 2 diabetes and colon cancer. *PPAR Res* 2017;2017:5879090. doi: 10.1155/2017/5879090
72. Call M, Fischesser K, Lunn M, Kao W. Notch regulation of PPAR-gamma and development of meibomian gland dysfunction. *Invest Ophthalmol Vis Sci* 2013;54(15):24